Biokin to Present at J.P. Morgan's 44th Annual Healthcare Conference

REDMOND, Wash., Jan. 13, 2026 /PRNewswire/ -- SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, today announced that its affiliate, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin) will present at the J.P. Morgan's 44^th Annual Healthcare Conference on Thursday, January 15, 2026 at 11:30am PST / 2:30pm EST.

The event will be webcast simultaneously at JPM 2026 SystImmune Webcast Presentation, with materials related to the presentation available at the start of the live webcast.  A replay and archived edition of the presentation will be available following the conclusion of the event.

About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located in Redmond, WA and Princeton, NJ. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor and hematologic indications. Alongside ongoing clinical trials, SystImmune has a robust preclinical pipeline of potential cancer therapeutics in the discovery or IND-enabling stages, representing cutting-edge biologics development.

View original content to download multimedia:https://www.prnewswire.com/news-releases/biokin-to-present-at-jp-morgans-44th-annual-healthcare-conference-302659846.html

SOURCE SystImmune, Inc.